Table 3 The 10 most prevalent prescription medication groups purchased by 271 primary health care centre patients in a randomised controlled trial. One prescription fill during the study period (365 days) was enough to be classified as a user
Name of medication group | Total No. users | Users in the intervention group (n = 132) | Users in the control group (n = 139) | Difference in proportion | 95% CI for difference in proportions | ||||
|---|---|---|---|---|---|---|---|---|---|
N | n | % | n | % | upper | lower | |||
M01A | Antiinflammatory and antirheumatic products, non-steroids | 92 | 41 | 31.1 | 51 | 36.7 | 5.6 | −0.05 | 0.17 |
N06A | Antidepressants | 91 | 41 | 31.1 | 50 | 36.0 | 4.9 | −0.06 | 0.16 |
A02B | Drugs for treatment of peptic ulcer | 58 | 25 | 18.9 | 33 | 23.7 | 4.8 | −0.05 | 0.15 |
N02B | Other analgesics and antipyretics | 57 | 27 | 20.5 | 30 | 21.6 | 1.1 | −0.08 | 0.12 |
N05B | Anxiolytics | 53 | 25 | 18.9 | 28 | 20.1 | 1.2 | −0.08 | 0.10 |
J01C | Beta-lactam antibacterials, penicillins | 49 | 27 | 20.5 | 22 | 15.8 | −4.7 | −0.13 | 0.05 |
N05C | Hypnotics and sedatives | 49 | 21 | 15.9 | 28 | 20.1 | 4.2 | −0.05 | 0.13 |
N02A | Opioids | 44 | 22 | 16.7 | 22 | 15.8 | −0.9 | −0.10 | 0.08 |
C07A | Beta blocking agents | 33 | 17 | 12.9 | 16 | 11.5 | −1.4 | −0.09 | 0.07 |
R06A | Antihistamines for systemic use | 29 | 11 | 8.3 | 18 | 12.9 | 4.6 | −0.02 | 0.12 |